Author

Pierre Fons

Observed names: FONS, Pierre, Fons, Pierre, Fons, Pierre (1880-1917), Fons, Pierre (1880-1917). Auteur du texte, Fons, Pierre, 1880-, P Fons, P. Fons

Observed institutions: University of London, Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier, Inserm, St George's, University of London, Technion – Israel Institute of Technology, Sanofi (France), Institut de Pharmacologie et de Biologie Structurale, Hôpital Purpan, Institut des Vaisseaux et du Sang

ORCID: 0000-0001-8079-7264

Observed ORCID: 0000-0001-8079-7264

OpenAlex ID: A5014157307

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

2009 · Fan Zhang, Zhongshu Tang, et al. · Proceedings of the National Academy of Sciences · 308

PDF

Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration

2006 · Benoit Favier, Antoine Alam, et al. · Blood · 293

Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells

2006 · P. Fons, S. Chabot, et al. · Blood · 201

Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors

2004 · Xuri Li, Marc Tjwa, et al. · Journal of Clinical Investigation · 172

Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties

2013 · Françoise Bono, Frederik De Smet, et al. · Cancer Cell · 146

PDF

Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity

2004 · Antoine Alam, Jean-Pascal Herault, et al. · Biochemical and Biophysical Research Communications · 68

PDF

Soluble HLA-G and control of angiogenesis

2007 · Philippe Le Bouteiller, Pierre Fons, et al. · Journal of Reproductive Immunology · 53

VEGF‐R2 and neuropilin‐1 are involved in VEGF‐A‐induced differentiation of human bone marrow progenitor cells

2004 · Pierre Fons, Jean‐Pascal Herault, et al. · Journal of Cellular Physiology · 32

Targeted Identification of Sialoglycoproteins in Hypoxic Endothelial Cells and Validation in Zebrafish Reveal Roles for Proteins in Angiogenesis

2014 · Nicolas Delcourt, Celia Quevedo, et al. · Journal of Biological Chemistry · 31

PDF

Tumor Vasculature Is Regulated by FGF/FGFR Signaling‐Mediated Angiogenesis and Bone Marrow‐Derived Cell Recruitment: This Mechanism Is Inhibited by SSR128129E, the First Allosteric Antagonist of FGFRs

2014 · Pierre Fons, Geneviève Gueguen‐Dorbes, et al. · Journal of Cellular Physiology · 26

Automated Image Analysis of In Vitro Angiogenesis Assay

2013 · Marie-Laure Boizeau, Pierre Fons, et al. · SLAS TECHNOLOGY · 15

PDF

Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy

2022 · Michael R. Paillasse, Michael Esquerré, et al. · Cancer Research Communications · 14

PDF

Baseline circulating myeloid-derived suppressor cells and response to PD-1 inhibitor in non-small cell lung cancer patients.

2018 · Myriam Delaunay, Nicolas Guibert, et al. · Journal of Clinical Oncology · 11

Abstract 1731: EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy

2021 · Andrew Payne, Pierre Fons, et al. · Cancer Research · 5

Abstract 3768: Identification of a novel non-brain penetrant A2AR inhibitor and proof-of-concept of CD73 and A2AR/CD73 small-molecule inhibitors for cancer immunotherapy

2018 · Pierre Fons, Andy Bell, et al. · Cancer Research · 5

Abstract 3970: Targeting the adenosine immunosuppressive pathway for cancer immunotherapy with small molecule agents

2017 · Pierre Fons, Michael Esquerré, et al. · Cancer Research · 5

Abstract 4150: Enriching for adenosine antagonist patient responses through deep learning

2022 · Isabella Alt, Robert Shelke, et al. · Cancer Research · 1

Abstract 4079: EVT801: a selective VEGFR3 inhibitor with the potential for combination with immune-checkpoint therapies, preclinical evidences and plans for first-in-human evaluation

2019 · Pierre Fons, Michael Esquerre, et al. · Cancer Research · 1

Abstract 519: EVOEXS21546 is a novel non-brain penetrant A2AR inhibitor for cancer immunotherapy with accelerated drug development

2019 · Pierre Fons, Andy Bell, et al. · Immunology · 1

Abstract 2634: EVT801: Standalone cancer immunotherapy in VEGFR3+ tumors and combination with immune checkpoint therapies in VEGFR3- tumors

2017 · Michael Esquerré, Pierre Fons, et al. · Cancer Research · 1

Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors

2004 · Xuri Li, Marc Tjwa, et al. · Journal of Clinical Investigation · 1

PDF

214eP Exploratory biomarkers evaluation to enhance characterization and explore treatment response prediction in metastatic ovarian cancer patients undergoing therapy with EVT801, a highly selective VEGFR-3 inhibitor

2025 · P. Fons, C.A. Gomez-Roca, et al. · Annals of Oncology

Abstract CT088: EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, is pursuing dose escalation stage of phase I first-in-human study

2024 · Carlos Gomez-Roca, Philippe Cassier, et al. · Cancer Research

Abstract 1059: Biomarkers analysis on samples from patients in EVT801 clinical trial: Patient characterization and immunomonitoring

2024 · Lise Davenne, Michael Fitzgerald, et al. · Cancer Research

137P VEGFR-3 expression profiling by histology and mRNA signature to classify patient population for the selective VEGFR-3 inhibitor EVT801

2023 · C.A. Gomez-Roca, P. Fons, et al. · Annals of Oncology

PDF

Works count: 73

Citation count: 1,390

H-index: 12

I10-index: 13